Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: Comparison of Ig/TCR rearrangements and the genomic fusion gene

Markus Metzler; Georg Mann; Uli Monschein; Martin Lodzinski; Christine Gall; Thomas Flohr; Susanne Viehmann; Thorsten Langer; Martin Schrappe; Helmut Gadner; Oskar A. Haas; E. Renate Panzer-Grümayer

Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: Comparison of Ig/TCR rearrangements and the genomic fusion gene

Markus Metzler, Georg Mann, Uli Monschein, Martin Lodzinski, Christine Gall, Thomas Flohr, Susanne Viehmann, Thorsten Langer, Martin Schrappe, Helmut Gadner, Oskar A. Haas, E. Renate Panzer-Grümayer^*

^*Corresponding author for this work

Clinic of Pediatric and Adolescent Medicine

16 Citations (Scopus)

Abstract

Quantification of minimal residual disease (MRD) based on clonotypic immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements is widely used as an independent prognostic parameter in childhood acute lymphoblastic leukemia (ALL). In this study we compared MRD by quantification of Ig/TCR targets and genomic ETV6-RUNX1 specific sequences. In ten of twelve patients with t(12;21)+ ALL we observed concordance with rapid blast reduction in nine, and high-level persistence in one case. The two remaining patients showed low-level persistence of the genomic breakpoint specific sequence. These patients have remained in complete remission for 38 and 41 months, so far, indicating that a small ETV6-RUNX1-positive clone is not detrimental to the short-term prognosis of affected children.

Original language	English
Journal	Haematologica
Volume	91
Issue number	5
Pages (from-to)	683-686
Number of pages	4
ISSN	0390-6078
Publication status	Published - 05.2006

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{beb91b15674f4933b6b34bfefa3e582b,

title = "Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: Comparison of Ig/TCR rearrangements and the genomic fusion gene",

abstract = "Quantification of minimal residual disease (MRD) based on clonotypic immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements is widely used as an independent prognostic parameter in childhood acute lymphoblastic leukemia (ALL). In this study we compared MRD by quantification of Ig/TCR targets and genomic ETV6-RUNX1 specific sequences. In ten of twelve patients with t(12;21)+ ALL we observed concordance with rapid blast reduction in nine, and high-level persistence in one case. The two remaining patients showed low-level persistence of the genomic breakpoint specific sequence. These patients have remained in complete remission for 38 and 41 months, so far, indicating that a small ETV6-RUNX1-positive clone is not detrimental to the short-term prognosis of affected children.",

author = "Markus Metzler and Georg Mann and Uli Monschein and Martin Lodzinski and Christine Gall and Thomas Flohr and Susanne Viehmann and Thorsten Langer and Martin Schrappe and Helmut Gadner and Haas, {Oskar A.} and Panzer-Gr{\"u}mayer, {E. Renate}",

year = "2006",

month = may,

language = "English",

volume = "91",

pages = "683--686",

journal = "Haematologica",

issn = "0390-6078",

number = "5",

}

TY - JOUR

T1 - Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: Comparison of Ig/TCR rearrangements and the genomic fusion gene

AU - Metzler, Markus

AU - Mann, Georg

AU - Monschein, Uli

AU - Lodzinski, Martin

AU - Gall, Christine

AU - Flohr, Thomas

AU - Viehmann, Susanne

AU - Langer, Thorsten

AU - Schrappe, Martin

AU - Gadner, Helmut

AU - Haas, Oskar A.

AU - Panzer-Grümayer, E. Renate

PY - 2006/5

Y1 - 2006/5

N2 - Quantification of minimal residual disease (MRD) based on clonotypic immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements is widely used as an independent prognostic parameter in childhood acute lymphoblastic leukemia (ALL). In this study we compared MRD by quantification of Ig/TCR targets and genomic ETV6-RUNX1 specific sequences. In ten of twelve patients with t(12;21)+ ALL we observed concordance with rapid blast reduction in nine, and high-level persistence in one case. The two remaining patients showed low-level persistence of the genomic breakpoint specific sequence. These patients have remained in complete remission for 38 and 41 months, so far, indicating that a small ETV6-RUNX1-positive clone is not detrimental to the short-term prognosis of affected children.

AB - Quantification of minimal residual disease (MRD) based on clonotypic immunoglobulin/T-cell receptor (Ig/TCR) gene rearrangements is widely used as an independent prognostic parameter in childhood acute lymphoblastic leukemia (ALL). In this study we compared MRD by quantification of Ig/TCR targets and genomic ETV6-RUNX1 specific sequences. In ten of twelve patients with t(12;21)+ ALL we observed concordance with rapid blast reduction in nine, and high-level persistence in one case. The two remaining patients showed low-level persistence of the genomic breakpoint specific sequence. These patients have remained in complete remission for 38 and 41 months, so far, indicating that a small ETV6-RUNX1-positive clone is not detrimental to the short-term prognosis of affected children.

UR - http://www.scopus.com/inward/record.url?scp=33744481524&partnerID=8YFLogxK

M3 - Journal articles

C2 - 16627248

AN - SCOPUS:33744481524

SN - 0390-6078

VL - 91

SP - 683

EP - 686

JO - Haematologica

JF - Haematologica

IS - 5

ER -

Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: Comparison of Ig/TCR rearrangements and the genomic fusion gene

Abstract

Research Areas and Centers

UN SDGs

Other files and links

Fingerprint

Cite this